Could a lupus drug tame autoimmune hepatitis?

NCT ID NCT06381453

First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This study tests whether adding belimumab (a drug approved for lupus) to standard therapy can better control autoimmune hepatitis, a chronic liver disease. About 48 adults with active or stable disease will receive weekly injections for 72 weeks. The goal is to reduce liver inflammation and lower the need for steroids or other immune-suppressing drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • G.I Research Institute

    RECRUITING

    Vancouver, British Columbia, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • London Health Sciences Centre

    RECRUITING

    London, Ontario, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • McMaster University

    RECRUITING

    Hamilton, Ontario, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Toronto General Hospital

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Calgary

    RECRUITING

    Calgary, Alberta, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.